MoonLake Immunotherapeutics (MLTX) was upgraded by Wolfe Research from "underperform" to "outperform". They now have a $24.00 price target on the stock.
MoonLake Immunotherapeutics (MLTX) was upgraded by Rothschild & Co Redburn from "neutral" to "buy". They now have a $40.00 price target on the stock.
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? [Yahoo! Finance]
MoonLake Immunotherapeutics (MLTX) had its price target raised by Royal Bank Of Canada from $12.00 to $13.00. They now have a "sector perform" rating on the stock.
Goldman Questions MoonLake Immunotherapeutics' (MLTX) Sonelokimab Approval Odds Despite Pipeline Update [Yahoo! Finance]